Friday, October 2, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleNasdaq· January 9, 2026

S&P 500 Rallies to a New Record High on US Economic Optimism

View original at nasdaq.com
S&P 500 Rallies to a New Record High on US Economic Optimism The S&P 500 Index ($SPX) (SPY) on Friday closed up +0.65%, the Dow Jones Industrials Index ($DOWI) (DIA) closed up +0.48%, and the Nasdaq 100 Index ($IUXX) (QQQ) closed up +1.02%…
Opening lines of the source · Nasdaq · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Qualcomm price target lowered to $175 from $200

    80% confidence
  • HealthEquity price target of $89

    80% confidence
  • AI market has over one and a half million AI models in the world

    80% confidence
  • Merck & Co is in talks to buy Revolution Medicines

    80% confidence
  • Expects 2026 global ARIKAYCE revenues between $450 million and $470 million

    80% confidence
  • US January consumer sentiment index rose to 54.0

    80% confidence
  • Southwest Airlines price target of $60

    80% confidence
  • Inflation is too high and we must ensure we don't lose sight of that concern despite labor market cooling

    80% confidence
  • Carvana price target raised to $750 from $700

    80% confidence
  • Q4 revenue forecast of $22.5 million to $23.5 million

    80% confidence
  • January 5-10 year inflation expectations rose to 3.4% from 3.2%

    80% confidence
  • US January 1-year inflation expectations unchanged at 4.2%

    80% confidence
  • Current level of interest rates can be assessed as appropriate

    80% confidence
  • Lockheed Martin price target of $605

    80% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI-Driven Drug Development Meets Biotech Deal-Making and Regulatory Catalysts
AI-designed therapeutics (Insilico's rentosertib showing biological-age reductions) are moving into the clinical mainstream. Large-cap biotech is simultaneously reallocating capital through M&A (Lilly–Merida, $2.9B) and government funding (BARDA–Basilea), while trial failures (ziltivekimab, a 9.4% Novo Nordisk share drop) and upcoming FDA catalysts (the ivonescimab PDUFA on 2026-11-14) drive volatility. The wider AI regulatory and legal climate (Tesla Cybercab probe, xAI's Minnesota loss, OpenAI suits) is tightening, though QAIAx's micro-cap trial claims are speculative and weakly connected.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,327 source documents archived
Query this data → isubstrate.com